Status: Recruiting
First in Human Dose Escalation Study Evaluating the Safety and Immunogenicity of IVT's Shigella-04 Vaccine in Healthy Young Adults
Phase 1 trial to evaluate the Safety and Immunogenicity of Inventprise's (IVT) Shigella-04 in Healthy Young Adults
Participants needed: 60
Trial details
Phase: Phase 1Age: 18-49Biological sex: AllType: InterventionalSponsor: Inventprise Inc.Updated: Nov 19, 2025Locations: 1
Eligibility criteria
Age 18 to 49 years at the time of Dose 1 [+7]
Currently lactating [+23]